As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran
US Decision Expected Before 2020 Ends
Novartis has pooled cholesterol control and safety data, but will have to wait longer for cardiovascular outcomes readout.
You may also be interested in...
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of developments in the global biopharmaceutical industry.
The RNA-drug developer, which is buying the approximately 24% of Akcea it doesn't already own for around $500m, highlighted the maturing pipeline in a cardiovascular overview.